Orum Therapeutics, Inc. (KOSDAQ:475830)

Market Cap	1.29T +137.5%
Revenue (ttm)	40.55M -99.8%
Net Income	18.51B
EPS	869.48
Shares Out	21.72M
PE Ratio	68.09
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	155,576
Open	63,500
Previous Close	65,000
Day's Range	58,500 - 64,100
52-Week Range	24,950 - 146,600
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 5, 2026

About Orum Therapeutics

Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases in South Korea and the United States. The company develops ORM-6151, which is in Phase I clinical trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes; ORM-1153, which is in pre-clinical trial for the treatment of acute myeloid leukemia and hematologic malignancies; and ORM-1023, which is in pre-clinical trial for the treatment of small cell lung cancer and neuroendocrine tumo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 475830

Financial Performance

In 2025, Orum Therapeutics's revenue was 23.56 million, a decrease of -99.89% compared to the previous year's 20.91 billion. Losses were -41.97 billion, 631.2% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 1, 2026

Data Sources Report a data error